Hepatorenal Syndrome > Pentoxyfylline

Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline

Recruiting in Palo Alto (17 mi)

Overseen By Jonathan G Stine, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Patrick Northup, MD

Trial Summary

What is the purpose of this trial?

Pentoxyfylline therapy in addition to the standard of care of albumin, midodrine and octreotide therapy is superior to the standard of care alone in the treatment of Type I hepatorenal syndrome in the first 14 days of hospitalization.

Eligibility Criteria

Inclusion Criteria

Hospitalized patients with acute or chronic liver disease

Type I HRS

Aged greater than or equal to 18

Participant Groups

Group I: Treatment Experimental Treatment 2 Interventions

Pentoxyfylline 400mg three times a day or 400mg twice a day for eGFR 10-50 and 400mg once a day for eGFR \<10 for 90 days in addition to standard AMO therapy

Group II: Placebo Placebo Group 2 Interventions

This is a standard placebo pill.

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

University of Virginia Health System Charlottesville, VA

Who Is Running the Clinical Trial?

Patrick Northup, MD Lead Sponsor

References